Michelle Dipp

Michelle Dipp is a Co-Founder and Managing Partner at Biospring Partners.
Michelle is passionate about life sciences and has over a decade of private equity and venture capital expertise.
She currently serves on the Board of Directors of two Biospring portfolio companies, Abzena and Kiniciti.
Prior to Biospring, Michelle was a Managing Director at General Atlantic where she launched their first life sciences investment platform and led multiple investments including Ginkgo BioWorks (NYSE:DNA), Motif FoodWorks, PathAI, Immunocore (NASDAQ:IMCR) and Ocumension (HK:1477).
Before starting the life sciences platform at General Atlantic, Michelle was Co-Founder and General Partner of Longwood Fund, a leading healthcare investment firm based in Boston.
Prior to Longwood, Michelle was the Senior Vice President of the CEEDD at GlaxoSmithKline (NASDAQ:GSK), leading global business development and M&A. GSK acquired Sirtris Pharmaceuticals, Inc. (NASDAQ:SIRT), where Michelle served as Vice President of Corporate Development.
?Michelle began her investment career at the Wellcome Trust after completing her medical training.
She holds a Bachelor of Medicine and Bachelor of Surgery from the University of Oxford Medical School and a Doctor of Philosophy in Human Physiology from the University of Oxford.